NCT06534060 - MB-105 in Patients With CD5 Positive T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

December 31, 2029

Conditions

Lymphoma, T-Cell

Interventions

BIOLOGICAL

Genetic: MB-105

MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.

Trial Locations (12)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

33612

RECRUITING

Moffitt Cancer Center Magnolia Campus, Tampa

44195

NOT_YET_RECRUITING

Cleveland Clinic, Cleveland

52242

RECRUITING

University of Iowa, Iowa City

68198

RECRUITING

University of Nebraska, Omaha

77030

RECRUITING

Baylor College of Medicine, Houston

RECRUITING

MD Anderson Cancer Center, Houston

92037

RECRUITING

University of San Diego (UCSD)-Moores Cancer Center, San Diego

NOT_YET_RECRUITING

SCRI - Colorado Blood Cancer Institute (CBCI), Denver

97239

NOT_YET_RECRUITING

Oregan Health & Science University, Portland

02114

RECRUITING

Massachusetts General Hospital, Boston